Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Sermorelin

GHRH (1-29), GRF 1-29 NH2, Sermorelin acetate

Quick Stats
Studies 223
Trials 41
Score 4
1988 pubmed 23 citations

Continuous subcutaneous growth hormone releasing factor analogue augments growth hormone secretion in normal male subjects with no desensitization of the somatotroph.

Brain. C C; Hindmarsh. P C PC; Brook. C G CG; Matthews. D R DR

Key Findings

  • Doses >30 ng/kg/min increase GH pulse amplitude and frequency
  • 60‑120 ng/kg/min provide the best dose‑response without desensitization
  • At 120 ng/kg/min GH levels stay elevated for many hours, showing no depletion of the releasable GH pool

Practical Outcomes

  • For biohackers, a continuous sub‑cutaneous pump delivering sermorelin at around 60‑120 ng/kg/min could be a more potent way to raise GH than intermittent injections, and you don’t seem to trigger tolerance over a week. This informs protocol design for those experimenting with GH‑boosting regimens, though the need for a pump and long‑term safety remain considerations.

Summary

A study gave healthy men a continuous skin‑pump infusion of the growth‑hormone‑releasing peptide sermorelin for eight days and found that doses above 30 ng/kg/min boosted both the size and number of GH spikes, with 60‑120 ng/kg/min being the most effective. Even the highest dose didn’t cause the body to stop responding, and GH stayed elevated for long periods, suggesting you can safely use higher, steady doses without the hormone system getting tired.

Abstract

The effects of 8 day continuous subcutaneous (s.c.) infusions of growth hormone releasing hormone analogue (NLE27GRF(1-29)NH2 (GHRH.A)) on growth hormone (GH) secretion were studied in 14 normal adult male volunteers. GHRH.A was administered in doses which ranged from 7.5 to 120 ng/kg/min in doubling steps. Baseline GH profiles obtained during a 24 h infusion of normal saline in each subject were compared with profiles performed on days 1 and 8 of the infusion. Doses above 30 ng/kg/min augmented GH pulse amplitude and frequency. Doses of 60 ng/kg/min and 120 ng/kg/min appeared more satisfactory as these represented doses on the upwards slope of the dose response curve. However, at a dose of 120 ng/kg/min the GH secretion did not return to baseline for 12 of the 24 h. There was no evidence of desensitization or of depletion of the releasable GH pool with any dose. The possibility of treatment of short children with depot preparations of GHRH.A appears promising.

Study Information

Provider

pubmed

Year

1988

Date

1988-05-01T00:00:00.000Z

DOI

10.1111/j.1365-2265.1988.tb03689.x

Citations

23

References

26